Executive Director, Pharmacovigilance

🕒 vor 8 Tagen

Jetzt Bewerben

Ähnliche Remote-Jobs finden

E-Mail-Benachrichtigung für neue Jobs einrichten

📊 Überprüfen Sie Ihre Lebenslauf-Bewertung für diese Stelle

Verbessern Sie Ihre Chancen auf ein Vorstellungsgespräch, indem Sie Ihre Lebenslauf-Bewertung vor der Bewerbung überprüfen.

Lebenslauf hochladen

SAB BIO

WebsiteLinkedInAlle Stellen

51 - 200 Mitarbeiter

Gegründet 2014

🧬 Biotechnologie

💊 Pharmazie

🏥 Gesundheitswesen

Biotechnology • Pharmaceuticals • Healthcare

SAB BIO ist ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung multi-spezifischer, hochwirksamer humaner Immunglobulin G (hIgG)-Therapien konzentriert, um Immun- und Autoimmunerkrankungen zu behandeln und zu verhindern. Ziel ist es, die Diagnose und Behandlung von Typ-1-Diabetes (T1D) durch krankheitsverändernde Medikamente neu zu definieren. Gegründet im Jahr 2014 und seit 2021 an der Nasdaq (SABS) notiert, nutzt SAB BIO proprietäre Technologien der genetischen Entwicklung und Antikörper zur Generierung therapeutischer Kandidaten, ohne auf menschliche Spender oder Rekonvaleszenz-Plasma angewiesen zu sein. Das Unternehmen hat sieben klinische Studien durchgeführt, in denen etwa 700 Personen in verschiedenen therapeutischen Bereichen dosiert wurden, und berichtet über keine Patienten mit Serumkrankheit oder neutralisierenden Anti-Drug-Antikörpern in seiner Sicherheits- und Immunogenitätsdatenbank. Der führende Kandidat, SAB-142, zielt darauf ab, das Fortschreiten von T3D im Stadium 3 zu verzögern und möglicherweise zu verhindern.

Beschreibung

• Lead and execute all PV activities for Phase 3 and registrational biologics programs, ensuring full compliance with ICH E2A, E2B, E2C, E2D, and E2E guidelines, as well as FDA, EMA, and other applicable regional requirements. • Oversee global signal detection, evaluation, and management activities, including Medical Dictionary for Regulatory Activities (MedDRA) coding review and benefit-risk assessment updates. • Manage and optimize safety data receipt, processing, and reporting workflows, including collaboration with CROs, data management teams, and clinical operations. • Serve as the subject-matter expert and primary PV point of contact for cross-functional clinical teams, regulatory affairs, and medical affairs. • Maintain and enforce the company's global safety database and adverse event reporting infrastructure, including oversight of vendor relationships. • Author and/or oversee the preparation of Integrated Safety Summaries (ISS) and Integrated Summaries of Efficacy (ISE) for BLA and MAA submissions (member of the submission team), ensuring scientific rigor, internal consistency, and full alignment with regulatory expectations (21 CFR 314.50, Module 2.7.4, ICH E3, ICH M4E). • Oversaw end-to-end safety labeling strategy for biologics, ensuring compliance with FDA, EMA, and other global regulatory requirements for products with boxed warnings, REMS, restricted access programs, and other post-marketing risk mitigation obligations. • Lead the development of Clinical Study Report (CSR) safety sections for Phase 2 and Phase 3 studies, including narrative writing, adverse event tabulations, and laboratory data analyses. • Prepare and manage Periodic Safety Update Reports (PSURs), Periodic Benefit-Risk Evaluation Reports (PBRERs), and Development Safety Update Reports (DSURs) on global schedules. • Prepare Risk Management Plans (RMPs) and Risk Evaluation and Mitigation Strategies (REMS), including strategy development and execution. • Respond to health authority questions and requests for safety information during regulatory review processes (e.g., Complete Response Letters, Day 120/180 questions).

🎯 Anforderungen

• Doctor of Medicine (MD) degree from an accredited institution is required. • 12+ years of progressive pharmaceutical/biotech industry pharmacovigilance experience, with at least 5 years in a senior role with direct accountability for late-phase global biologics PV programs. • Demonstrated hands-on authorship of Integrated Safety Summaries (ISS) submitted in at least one BLA or MAA; experience with multiple submissions strongly preferred. • Extensive experience authoring CSR safety sections, DSURs, and PSURs/PBRERs for biologic compounds in global development. • Deep command of ICH guidelines (E2A–E2E, E6, E8, M4E), FDA/CDER and EMA/EMA GVP Module requirements, and regional pharmacovigilance regulations (EU, US, Japan, and other ICH regions). • Extensive experience with signal detection methodologies, benefit-risk assessment frameworks, and safety narrative writing. • Proven track record managing CRO/vendor PV relationships and safety database oversight (Argus, ARISg, or equivalent). • Experience in small biotech or start-up environments is desired; comfortable operating with limited infrastructure and high personal accountability. • Experience with BLA or MAA approval for a biologic; post-approval PV experience a plus. • Familiarity with rare disease, orphan drug, or first-in-class biologic programs. • Experience presenting to Health Authorities (FDA, EMA) and participation in Advisory Committee proceedings. • Familiarity with REMS design and implementation or EU RMP preparation. • Knowledge of pharmacoepidemiology methodologies and real-world evidence applications in safety assessment. • Exceptional scientific and medical writing ability; proven capacity to synthesize complex safety data into clear, structured regulatory documents under tight timelines. • Strong analytical and critical thinking skills; ability to independently evaluate complex safety signals and formulate evidence-based recommendations. • High scientific credibility with the ability to engage and challenge clinical, statistical, and regulatory colleagues at a peer level. • Excellent project management skills; able to manage multiple competing priorities without sacrificing quality. • Demonstrated leadership and cross-functional collaboration is crucial.

🏖️ Vorteile

• Home office working environment • Domestic and International business related to travel (estimated 10–20%) • ADA: The employer will make reasonable accommodations in compliance with the Americans with Disabilities Act of 1990.